United States

Cronos Clinical Consulting Services relocates

Tuesday, August 13, 2013 11:00 AM

Cronos Clinical Consulting Services, a global neuroscience-focused clinical data quality control organization, has relocated headquarters to Lambertville, N.J.

More... »

CollabRx launches clinical cancer sequencing commercial service

Monday, August 12, 2013 01:17 PM

CollabRx, a data analytics company focused on informing clinical decision making in molecular medicine, has launched the Genetic Variant Annotation (GVA) service. The service is a new product and the company's first offering for the clinical laboratory market. CollabRx will provide GVA to the molecular diagnostic segment of the clinical laboratory market, which includes reference laboratories, hospital laboratories, research institutions and laboratories within academic medical centers.

More... »

Alan Copa joins Novum as vice president

Friday, August 9, 2013 01:56 PM

Dr. Alan Copa has joined the leadership team of CRO Novum Pharmaceutical Research Services as vice president. Previously, Copa was chief scientific officer of PRACS Institute. In his 20-year tenure at the company, Copa had numerous clinical and operational lead roles, and was Principal Investigator on 1,000 projects spanning early phase, dermatology and pharmacokinetics.

More... »

MedNet Solutions, Heart Imaging Technologies partner

Friday, August 9, 2013 01:08 PM

MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, and Heart Imaging Technologies (Heart IT),  providing web-based medical image viewing and management solutions, have  partnered to  integrate Heart IT's WebPAX technology with MedNet's eClinical solutions.  This integration improves the speed, accuracy and efficiency of clinical trials that rely on the collection and analysis of DICOM images.

More... »

Covance launches managed markets services

Friday, August 9, 2013 01:04 PM

Princeton, N.J.-based CRO Covance has created a new service offering focused on providing its biopharmaceutical and medical device clients support to effectively manage contracts in managed markets.

More... »

23andMe launches national TV campaign

Friday, August 9, 2013 12:55 PM

23andMe, a personal genetics company, has launched Portraits of Health, the company’s first television advertising campaign. The campaign focuses on educating consumers about how understanding their DNA can help them make more informed and proactive health decisions.

More... »

Berg, Department of Defense partner for prostate cancer research

Friday, August 9, 2013 12:48 PM

Berg, a biopharmaceutical company researching health solutions through a data-driven, biological research approach, has partnered with the U.S. Department of Defense (DoD) under a cooperative R&D agreement with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) for prostate cancer research.

More... »

NuMe Health becomes MicroBiome Therapeutics

Wednesday, August 7, 2013 11:36 AM

NuMe Health has changed its name to MicroBiome Therapeutics and has hired Steve Orndorff, Ph.D., as chief executive officer.

More... »

S1 Biopharma doses first patients in phase IIa trial of Lorexys

Tuesday, August 6, 2013 12:30 PM

S1 Biopharma, a developer of first-in-class drugs for sexual dysfunction in women and men, has announced enrollment and dosing of premenopausal women with hypoactive sexual desire disorder (HSDD) in the phase IIa clinical trial of its leading drug candidate Lorexys (S1P-104).

More... »

Arisaph awarded phase I STTR grant

Tuesday, August 6, 2013 11:06 AM

Arisaph Pharmaceuticals, a privately held drug discovery and development biopharmaceutical company focused on developing novel therapies for cardiometabolic diseases and cancer, has been awarded a phase I Small Business Technology Transfer (STTR) award from the National Cancer Institute of the NIH. The award supports the R&D of Arisaph's small molecule immune modulators to stimulate tumor immunity following treatment with BRAF inhibitors in cancer.  

More... »